Ask AI
ProCE Banner Activity

Navigating Relapsed/Refractory Multiple Myeloma: Real-world Use of Bispecific Antibodies

Podcast Episodes

Listen to Doris K. Hansen, MD, discuss the management of relapsed/refractory multiple myeloma with bispecific antibodies.

Released: May 15, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Johnson & Johnson

Target Audience

This activity's target audience includes community hematologists/oncologists and other healthcare professionals responsible for the care and treatment of patients with relapsed refractory multiple myeloma.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Analyze the criteria for R/R MM diagnosis and the subsequent process for timely initiation of care, emphasizing the importance of early intervention

  • Demonstrate proficiency in the handling, administration, and transitioning care of BsAbs from academic to community settings, ensuring continuity of care

  • Evaluate the available clinical data on BCMA BsAbs, interpreting insights into their efficacy, appropriate dosing, and adverse events (AEs) profiles for informed decision-making

  • Identify the key risk factors associated with treatment-specific AEs related to BsAbs and formulate evidence-based strategies for timely identification and effective management

  • Advocate for equity in R/R MM treatment by recognizing disparities in care, highlighting experiences with BsAbs, and promoting strategies that ensure equitable access to treatment for diverse and underrepresented patient populations

Disclosure

Primary Author

Doris K. Hansen, MD: consultant/advisor/speaker: AstraZeneca, Bristol Myers Squibb, Janssen, Karyopharm, Kite/Gilead Sciences, Legend Biotech; researcher: Adaptive, Bristol Myers Squibb, Janssen, Karyopharm, Kite/Gilead Sciences.